← Back to Search

Antisense Oligonucleotide

STP705 for Keloid

Phase 2
Waitlist Available
Led By Mark Nestor, MD
Research Sponsored by Sirnaomics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months

Summary

This trial tests STP705 injections to prevent keloids from returning after removal in adults with long-standing keloid scars on their trunk or extremities. The treatment works by reducing inflammation and stopping new scar tissue from forming.

Eligible Conditions
  • Keloid

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Rate of Recurrence
Secondary study objectives
Change in DLQI score
Change in mVSS score
Change of Keloid scar appearance
+2 more

Trial Design

6Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Cohort 4: STP705 40 μg doseExperimental Treatment1 Intervention
STP705 at the assigned dose will be injected intradermal into the excised keloid site
Group II: Cohort 3: STP705 30 μg doseExperimental Treatment1 Intervention
STP705 at the assigned dose will be injected intradermal into the excised keloid site
Group III: Cohort 2: STP705 20 μg doseExperimental Treatment1 Intervention
STP705 at the assigned dose will be injected intradermal into the excised keloid site
Group IV: Cohort 1: STP705 10 μg doseExperimental Treatment1 Intervention
STP705 at the assigned dose will be injected intradermal into the excised keloid site
Group V: Cohort 6: SOC aloneActive Control1 Intervention
SOC (no injection)
Group VI: Cohort 5: Placebo controlPlacebo Group1 Intervention
Placebo (saline) will be injected intradermal into the excised keloid site
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
STP705
2022
Completed Phase 2
~180

Find a Location

Who is running the clinical trial?

SirnaomicsLead Sponsor
11 Previous Clinical Trials
308 Total Patients Enrolled
Mark Nestor, MDPrincipal InvestigatorCenter for Clinical and Cosmetic Research
3 Previous Clinical Trials
61 Total Patients Enrolled
David Goldberg, MDPrincipal InvestigatorSchweiger Dermatology Group
3 Previous Clinical Trials
118 Total Patients Enrolled
~7 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top